Clinical Trial

HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal Metastasis

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 16, 2022 (before its estimated March 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the Safety and Efficacy of HIPEC Combined With Sintilimab for Gastric Cancer Patients with Peritoneal Metastasis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-12-05.
Trial Details
NCT Number NCT05648487
Lead Sponsor Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Conditions Gastric Cancer
Enrollment 46 participants
Start Date 2023-01-01
Primary Completion 2025-03-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2022-12-16